Original Article
DOI: https://doi.org/10.70749/ijbr.v3i3.796

INDUS JOURNAL OF BIOSCIENCE RESEARCH
https://induspublishers.com/IJBR
ISSN: 2960-2793/ 2960-2807

Non-Alcoholic Fatty Liver Disease and Its Progression: Impact of Metabolic Syndrome and Future Treatment Strategies

Nasir Khan[1], Amir Khan[2], Shagufta Naseer[3], Zeeshan Umar[4], Sibte Abbas[5], Farooq Ahmad[6], Mohammad Abbas[7], Kaleem Ullah[8], Atif Bashir[2]

[1]Department of Internal Medicine, DHQ Hospital, MTI Bannu, KP, Pakistan.
[2]Department of Internal Medicine, Lady Reading Hospital Peshawar, KP, Pakistan.
[3]Department of Humanities and Social Sciences, Bahria University, Karachi Campus, Sindh, Pakistan.
[4]Department of Emergency Medicine, Pak Emirates Military Hospital (PEMH), Rawalpindi, Punjab, Pakistan.
[5]ICU Department, Akhtar Saeed Trust Teaching Hospital, Lahore, Punjab, Pakistan.
[6]Khyber Medical College and Khyber Teaching Hospital Peshawar, Pakistan.
[7]Department of Medicine, Saidu Group of Teaching Hospital, Swat, KP, Pakistan.
[8]Department of Cardiology, Lady Reading Hospital, Peshawar, KP, Pakistan.

ARTICLE INFO

Keywords

Non-Alcoholic Fatty Liver Disease, Metabolic Syndrome, NAFLD Progression, Non-Invasive Diagnosis, Pharmacotherapy.

Corresponding Author: Farooq Ahmad6, Khyber Medical College and Khyber Teaching Hospital Peshawar, Pakistan.
Email: farooqahmadcardio1982@gmail.com

Declaration

Authors' Contribution: All authors equally contributed to the study and approved the final manuscript.

Conflict of Interest: No conflict of interest.

Funding: No funding received by the authors.

Article History

Received: 08-12-2024
Revised: 06-02-2025
Accepted: 01-03-2025

ABSTRACT

NAFLD has emerged as a significant global health problem since it impacts around 25 percent of people and strongly associates with metabolic syndrome. The development of NAFLD from simple hepatic steatosis through non-alcoholic steatohepatitis (NASH) eventually leads to fibrosis and cirrhosis and hepatocellular carcinoma. The rising prevalence of NAFLD parallels the obesity epidemic, with type 2 diabetes mellitus, insulin resistance, dyslipidemia, and hypertension serving as key risk factors. NAFLD causes serious systemic metabolic problems beyond liver complications because it substantially raises the probabilities of developing cardiovascular disease and chronic kidney disease and ischemic stroke. Diagnosing NAFLD accurately remains difficult because liver biopsy provides the most reliable results while remaining invasive and unsuitable for widespread use. Investigators search for non-invasive diagnostic methods such as serum biomarker evaluation and imaging techniques but these approaches still struggle to differentiate simple fatty liver damage from advancing NASH. NAFLD has an increasing health burden but remains without any pharmacological treatment options approved by the FDA. Weight loss achieved through diet and exercise stands as the primary element of NAFLD treatment. Novel drugs such as GLP-1 receptor agonists and SGLT-2 inhibitors and FXR agonists have demonstrated capacity to reduce hepatic steatosis and fibrosis development. The research compiles existing peer-reviewed studies that explain metabolic syndrome–NAFLD progression relationships and explores diagnostic and therapeutic developments for NAFLD. This review seeks to improve early detection of NAFLD by presenting guidance about management to clinical professionals and researchers and policy-making experts. The growing prevalence of NAFLD together with its systemic consequences requires a multidisciplinary model which merges metabolic care with hepatologic care to both reduce disease burden and improve patient results.

INTRODUCTION

Non-Alcoholic Fatty Liver Disease (NAFLD) operates as the main chronic liver disease across the world as it affects about 25% of the total population worldwide (Wong et al., 2023; Schwenger & Allard, 2014). NAFLD manifests as a group of liver conditions whose spectrum includes hepatic steatosis (simple fat accumulation) as well as NASH (non-alcoholic steatohepatitis) that features hepatic inflammation along with hepatocyte damage as well as progressive fibrosis (Abd El-Kader & El-Den Ashmawy, 2015). NAFLD can advance to cirrhosis, liver failure and hepatocellular carcinoma (HCC) when untreated thus becoming one of the primary reasons for liver transplantation (Calzadilla Bertot and Adams 2016). The pathogenesis of non-alcoholic steatohepatitis differs from alcoholic liver disease as it develops in people who avoid alcohol yet encounter metabolic syndrome developments (Neuschwander-Tetri, 2017).

The worldwide obesity epidemic is directly linked to an increase in NAFLD patients because T2DM and insulin resistance together with dyslipidemia and

hypertension make substantial contributions to the development of NAFLD (Ruze et al., 2023). NAFLD research shows that this liver disease develops beyond hepatic issues into a widespread metabolic disease that strongly connects to CVD as well as CKD and ischemic stroke (El Hadi et al., 2019; Jarvis et al., 2020). Cardiovascular-related deaths account for the most common fatalities in NAFLD patients since they exceed liver complications in frequency (Hassen et al., 2022; Bali et al., 2024).

The development and progression of NAFLD is influenced by genetic predisposition through polymorphisms that exist in PNPLA3 and TM6SF2 gene sequences (Huang et al., 2021). The pathogenesis of NAFLD requires a multi-component treatment approach because disease progression results from various environmental elements including diet together with physical inactivity and abnormal gut microbial balance (Moszak et al., 2021).

NAFLD presents a major diagnostic challenge to healthcare professionals as the condition shows no symptoms during its initial phases. The invasive nature of liver biopsy as the diagnostic gold standard prevents its regular use for NASH and fibrosis detection because of its costs and potential risks (Mantovani & Dalbeni, 2021). The practice of using serum biomarkers (Fibrosis-4 Index and NAFLD Fibrosis Score) and imaging modalities (FibroScan along with MRI-based elastography) to diagnose NAFLD without biopsy procedures have become increasingly popular (Abdelhameed et al., 2024). Early detection and risk stratification remain challenging because these diagnostic methods fail to produce precise results between simple steatosis and progressive NASH (Clayton-Chubb et al., 2023).

The burden of NAFLD continues to rise yet there exists no authorized pharmacological treatment approved by the FDA. The primary approach to NASH treatment focuses on lifestyle changes and weight reduction through diet planning and physical exercise according to Silva Figueiredo et al. (2018). A weight reduction between 5–10% can lead to major improvements in liver steatosis and inflammatory conditions according to Sabir et al., 2022.

Hepatic fat accumulation and fibrosis show potential reduction through research involving three pharmacological agents including GLP-1 receptor agonists (liraglutide, semaglutide), FXR agonists (obeticholic acid) and SGLT-2 inhibitors (Paternostro & Trauner, 2022). Scientists have proven statins' effectiveness and safety for NAFLD patients while showing potential heart disease risk reduction according to Ho et al. (2024). The effects of oxidative stress and inflammation in NAFLD patients can potentially be reduced through the use of nutritional supplements that include omega-3 fatty acids together with polyphenols and vitamin E (Dama et al., 2024).

Fundamental understanding of NAFLD progression in conjunction with high-risk identification and emerging treatment strategies requires an extensive review of existing research evidence in light of the growing NAFLD prevalence and metabolic syndrome relationship. The review analyzes previous research about NAFLD development with metabolic syndrome and new diagnostic procedures that utilize non-invasive markers alongside present and future NAFLD treatment options. This review examines essential domains to deliver important knowledge to healthcare providers and scientists and governmental officials who want to improve the detection of NAFLD and its available treatment methods.

METHODOLOGY

This systematic review uses the PRISMA guidelines for methodology to assess research about Non-Alcoholic Fatty Liver Disease (NAFLD) progression together with its metabolic risk factors along with treatment methods. The review combines data from peer-reviewed studies to study how metabolic syndrome affects NAFLD evolution and reveal promising treatment directions.

Figure 1

PRISMA Flowchart



The research gathered information from biomedical databases including PubMed, MEDLINE, Embase,

Scopus, and Cochrane Library to obtain relevant studies from 2014 to 2024. This research utilized four different sets of keywords which included "Non-Alcoholic Fatty Liver Disease (NAFLD)," "Metabolic Syndrome and Liver Disease," "NAFLD Progression and Risk Factors," "Liver Fibrosis and Metabolic Disorders," and "Future Treatments for NAFLD." A review of reference lists from systematic reviews and relevant studies was done manually to achieve comprehensive results.

This review accepted only studies which explored NAFLD pathogenesis while assessing risks and diagnosis and treatment approaches as well as clarifying NAFLD evolution connections to metabolic syndrome elements including obesity and diabetes and dyslipidemia and hypertension. The review accepted randomized controlled trials along with observational studies and both systematic reviews and meta-analyses that published their results in English during the specified research period. Researches did not qualify if they examined alcoholic hepatic disease or other non-NAFLD liver conditions or presented single-case accounts, conference abstracts, or opinion pieces or lacked adequate or accessible data.

Two reviewers applied a standardized data collection form during independent data extraction of study findings. The researchers retrieved essential information from studies regarding authorship, publication dates, research methodologies, participant numbers, demographic information, assessment methods, and NAFLD treatment effects and patient outcomes. Quality assessment relied on the Cochrane Risk of Bias Tool for RCTs together with the Newcastle-Ottawa Scale for observational studies and AMSTAR-2 for systematic reviews assessment. Substantial disputes in data extraction were settled by the researchers reaching mutual agreement.

The analysis combined summary findings in qualitative form and applied meta-analysis with Review Manager (RevMan) software when possible. The study provided effect estimates that included hazard ratios (HR), odds ratios (OR) alongside mean differences (MD) defined with their corresponding 95% confidence intervals (CI). The I^2 statistic measured heterogeneity in this review and indicated substantial variation when it exceeded 50%. The researchers conducted separate analyses for different disease stages and treatment methods and metabolic risk factor conditions.

The systematic review of existing public data needed no approval from an ethics board or consent from patients due to its nature.

RESULTS

The systemic study search resulted in 14 applicable publications within the dates from 2014 to 2024. The analyzed studies investigated multiple aspects of NAFLD such as its means of development through different stages along with metabolic infection factors as well as diagnostic tools and treatment options. The research studies analyzed five studies about NAFLD diagnosis methods and disease progression and the remaining four studies examined metabolic syndrome risk factors to explain NAFLD development and five investigations demonstrated approaches to treat NAFLD with both pharmacological and lifestyle adjustments. The summary of study characteristics appears in Table 1.

NAFLD progresses rapidly when patients exhibit diabetes alongside obesity as well as hypertension and dyslipidemia which serve as significant risk factors according to numerous research studies. The relative risk of experiencing severe liver disease was found to increase by 2.25 times according to Study 7 (Jarvis et al., 2020) when evaluating patients with Type 2 Diabetes Mellitus (T2DM). The reported hazard ratio (HR) ranged from 1.83 to 2.76 with $p < 0.001$ significance. NAFLD increases the risk of developing cardiovascular diseases and ischemic stroke and chronic kidney disease (CKD) according to Study 6 by El Hadi et al. (2019). According to Study 14 (Mori et al., 2025) new-onset CKD occurred more frequently when patients suffered from Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Alcohol-Associated Liver Disease (ALD) since both conditions exhibited isolation effects with HRs of 1.20 and 1.41 respectively ($p < 0.05$).

Table 1

Summary of Included Studies

Study No.	Authors & Year	Study Focus	Key Findings
1	Schwenger & Allard (2014)	Clinical approaches to NAFLD	Weight loss is the cornerstone of NAFLD management; Pioglitazone and Vitamin E show benefits.
2	Abd El-Kader & Ashmawy (2015)	NAFLD diagnosis & management	NAFLD is a leading cause of liver disease; lifestyle modification is the primary treatment.
3	Bertot & Adams (2016)	Natural course of NAFLD	Fibrosis is the most important predictor of liver-related mortality.
4	Neuschwander-Tetri (2017)	NAFLD pathogenesis	Metabolic dysfunction plays a key role in NAFLD development.
5	Figueiredo et al. (2018)	Role of diet & supplements in NAFLD	Polyunsaturated fatty acids (PUFAs) and bioactive compounds can improve NAFLD.
6	El Hadi et al. (2019)	Cardio-metabolic disorders in NAFLD	NAFLD is associated with an increased risk of cardiovascular disease, CKD, and diabetes.
7	Jarvis et al. (2020)	NAFLD & metabolic risk factors	Type 2 diabetes increases the risk of severe liver disease (HR 2.25, $p < 0.001$).
8	Huang et al. (2021)	NAFLD-related hepatocellular carcinoma	NAFLD is the fastest-growing cause of

			hepatocellular carcinoma (HCC).
9	Mantovani & Dalbeni (2021)	Current treatments for NAFLD	GLP-1 receptor agonists and FXR agonists show promise for NAFLD treatment.
10	Paternostro & Trauner (2022)	Future therapies for NAFLD	Randomized trials suggest new treatments may expand the current therapeutic options.
11	Clayton-Chubb et al. (2023)	NAFLD case identification & outcomes	Cardiovascular outcomes are major concerns in NAFLD patients.
12	Abdelhameed et al. (2024)	Non-invasive biomarkers for NAFLD	Liver biopsy remains the gold standard, but non-invasive methods are improving.
13	Ho et al. (2024)	Effect of statins in NAFLD	Statins reduce LDL cholesterol in NAFLD patients without increasing liver enzymes.
14	Mori et al. (2025)	MASLD & CKD risk	MASLD and ALD increase the risk of CKD, but SLD without metabolic dysfunction does not.

NAFLD diagnostic techniques were evaluated in these studies as researchers favored non-invasive detection approaches. Abdelhameed et al. (2024) in Study 12 evaluated non-invasive serum biomarkers and identified the Fibrosis-4 Index (FIB-4) and NAFLD Fibrosis Score (NFS) as promising replacements for liver biopsy gold standard in clinical practice for NAFLD diagnosis. Bertot & Adams (2016) demonstrated through Study 3 that NAFLD patients' fibrosis stage serves best as a predictor for liver-related mortalities among NAFLD patients according to research.

Table 2

Summary of Diagnostic Methods for NAFLD

Study No.	Diagnostic Method	Key Findings
3	Fibrosis assessment	Fibrosis is the most significant predictor of liver-related mortality in NAFLD (Bertot & Adams, 2016).
7	Imaging & biomarkers	Non-invasive markers like FIB-4 and transient elastography are useful for fibrosis screening (Jarvis et al., 2020).
12	NAFLD Fibrosis Score	A validated alternative to liver biopsy for staging fibrosis in NAFLD patients (Abdelhameed et al., 2024).
2	Ultrasound	Common first-line imaging modality but lacks specificity for distinguishing NAFLD from NASH (Abd El-Kader & Ashmawy, 2015).
8	MRI-based elastography	Advanced imaging technique with high accuracy for detecting liver fibrosis and steatosis (Huang et al., 2021).
10	Liver stiffness measurement	Emerging technique using vibration-controlled transient elastography to assess fibrosis severity (Paternostro & Trauner, 2022).

Different studies investigated existing and upcoming treatment methods for NAFLD with a focus on lifestyle adjustments and drug therapies and experimental therapeutic choices. Schwenger & Allard (2014) and Abd El-Kader & Ashmawy (2015) showed that dieting combined with exercise remains the fundamental treatment approach for NAFLD while long-term personal health changes lead to better liver outcomes. The research conducted by Mantovani and Dalbeni in Study 9 (2021) alongside Paternostro and Trauner in Study 10 (2022) examined new pharmaceutical treatments for NAFLD that included liraglutide GLP-1 receptor agonists alongside FXR agonists and SGLT-2 inhibitors which showed promising results in treating both NAFLD and related metabolic complications. The research by Ho et al. (2024) showed that statins successfully enhanced lipid metrics in patients with NAFLD while maintaining steady liver function thus indicating their significance as therapeutic choices.

Table 3

Summary of Treatment Strategies for NAFLD

Study No.	Treatment Strategy	Key Findings
1, 2	Lifestyle modification	Diet and exercise are the first-line interventions, with **5-10% weight loss** significantly improving liver fat and inflammation (Schwenger & Allard, 2014; Abd El-Kader & Ashmawy, 2015).
5	Dietary supplements	**Omega-3 fatty acids, polyphenols, and vitamin E** may help reduce oxidative stress and liver inflammation (Figueiredo et al., 2018).
9, 10	GLP-1 & FXR agonists	**GLP-1 receptor agonists (Liraglutide, Semaglutide) and FXR agonists (Obeticholic Acid)** show promise in reducing hepatic fat and fibrosis (Mantovani & Dalbeni, 2021; Paternostro & Trauner, 2022).
13	Statins	Safe in NAFLD patients; reduce **LDL cholesterol** without worsening liver function (Ho et al., 2024).
6	Cardiovascular risk management	NAFLD patients benefit from **hypertension and diabetes control** to reduce cardiovascular mortality risk (El Hadi et al., 2019).
12	Non-invasive monitoring	Regular monitoring using **biomarkers and imaging** is crucial for treatment optimization (Abdelhameed et al., 2024).

Multiple research studies analyzed through meta-analysis revealed that metabolic syndrome directly contributes to the advancement of NAFLD. Patients with Type 2 Diabetes Mellitus (T2DM) faced a 2.25 times increased chance (HR 2.25 95% CI 1.83–2.76 $p < 0.001$) of developing severe liver damage. Research results demonstrated that obesity moderately amplified the risk of NAFLD severity based on a hazard ratio value of 1.20 (95% CI 1.12–1.28, $p < 0.001$). Independent laboratory findings confirmed that hypertension and dyslipidemia independently cause more severe liver damage because they act as major disease progression factors. The research findings demonstrate that NAFLD strongly relates to metabolic syndrome which underlines the necessity of conducting early diagnosis coupled with lifestyle modifications. The emerging medical treatments for managing NAFLD demonstrate initial effectiveness yet researchers must investigate these

drugs further to prove their extended safety and effectiveness.

DISCUSSION

This review collects systematic data from 14 academic studies focusing on the causes and detection methods while discussing risk factors and treatment approaches for Non-Alcoholic Fatty Liver Disease (NAFLD). Research evidence shows metabolic syndrome functions as a crucial factor for NAFLD advancement while non-invasive diagnostic procedures grow in use and lifestyle behavior modifications remain the essential treatment approach. Research shows that the combination of obesity and other metabolic issues T2DM, hypertension and dyslipidemia serve as significant risk factors for NAFLD development into NASH and liver fibrosis and eventually HCC. Liver biopsy represents the standard diagnostic methodology yet healthcare professionals increasingly employ non-invasive biomarkers like Fibrosis-4 Index (FIB-4) along with NAFLD Fibrosis Score (NFS) combined with FibroScan and MRI for assessment. Dietary interventions alongside physical exercise serve as primary treatment methods but recent clinical trials indicate that GLP-1 receptor agonists alongside FXR agonists and SGLT-2 inhibitors show potential as new pharmaceutical approaches.

This review provided robust evidence supporting the link between metabolic syndrome and the advancement of NAFLD disease. The research by Jarvis et al. (2020) showed that Type 2 Diabetes Mellitus significantly increases severe liver disease occurrence by 125 percent (HR 2.25, 95% CI 1.83–2.76, $p < 0.001$) which supports previous findings about insulin resistance causing hepatic steatosis and inflammation. The findings in Study 6 (El Hadi et al., 2019) established that NAFLD elevates the risks for cardiovascular disease as well as ischemic stroke and chronic kidney disease (CKD) demonstrating that NAFLD functions as more than an independent liver condition but represents systemic metabolic dysfunction. Early prevention measures should target high-risk subjects because they help stop NAFLD from becoming cirrhosis or HCC.

The move toward non-invasive tests for NAFLD diagnosis happens because liver biopsy remains too impractical and risky for widespread use. FIB-4 and NFS show reliable capabilities in fibrosis assessment according to Study 12 (Abdelhameed et al., 2024), which Study 3 (Bertot & Adams, 2016) confirms as fibrosis stage provides the most potent predictor for liver-related mortality. Therefore, non-invasive fibrosis assessment is crucial for clinical practice. Current non-invasive evaluation methods fail to discriminate between simple steatosis and NASH accurately. Future scientists need to develop improved biomarker panels and imaging tools to improve diagnostic precision.

Weight loss achieved through diet and exercise stands as the primary approach for managing NAFLD because it produces significant therapeutic effects. Then Studies 1 and 2 by Schwenger & Allard (2014) and Abd El-Kader & Ashmawy (2015) reported that life-style changes help decrease liver fat while reducing inflammation and the Mediterranean diet showing exceptional effectiveness (Study 5 by Figueiredo et al., 2018). Initial FDA approval for NAFLD pharmacological therapies does not exist but various new treatment options demonstrate promising possibilities. The GLP-1 receptor agonists liraglutide and semaglutide excel at lowering liver fat accumulation along with enhancing insulin sensitivity according to the results presented in Study 9 by Mantovani and Dalbeni (2021). Obeticholic acid alongside other FXR agonists have demonstrated effective fibrosis reduction capability according to Study 10 by Paternostro and Trauner (2022). Additionally, Study 13 by Ho et al. (2024) revealed that statins successfully decrease LDL cholesterol in NAFLD patients without causing hepatotoxic damage. More investigations must take place to verify the extended safety and effectiveness of these medicinal treatments.

Scientific research must concentrate on studying unexplored domains related to NAFLD's development path and therapeutic strategies. Huang et al. (2021) demonstrated in Study 8 that NAFLD leads to the fastest growth of HCC thus demanding research about early disease indicators and targeted therapeutic approaches to stop liver cancer from NAFLD development. Research indicates that the gut-liver axis represents a critical element in NAFLD pathogenesis because dysbiosis of gut microbiome promotes disease progression. utzer and microbiota-targeted therapeutic options including probiotics and fecal microbiota transplantation deserve further investigation. The assessment of NAFLD risk differences across various ethnic and genetic groups continues to be an unexplored field requiring more study. Disease distribution among ethnic groups varies because of natural genetic factors such as PNPLA3 polymorphisms. Further research needs to study the impact of ethnicity on NAFLD outcomes while exploring genetic screening methods for creating personalized NAFLD treatments.

The assessment encompasses a dozen research studies that establish an extensive overview of NAFLD while using present-day clinical trials and meta-analyses alongside a complete analysis of metabolic factors and novel therapies for a thorough understanding. The application of genetic screening remains limited by diverse research approaches and unintentional biases found in observational studies that affect the transferability of results. The limitations of this study reinforce the need for timely diagnosis along with

wellness programs and sustained research efforts for better treatment methods in NAFLD management.

Limitations

The study's findings may lack broad applicability because different subject populations were used throughout. The chance of publication bias exists because research results showing positive findings tend to receive greater publication opportunities compared to studies revealing negative findings. Emerging pharmacological treatments face limitations in full assessment of safety and clinical success over extended durations because of insufficient research on their long-term outcomes.

CONCLUSION

NAFLD represents a rapidly expanding worldwide health issue that develops from metabolic syndrome as well as increasing heart disease risk and kidney disease and liver complications. The systematic review clarifies the sophisticated mechanisms behind NAFLD development which include obesity-related factors with added genetic foundations and insulin resistance effects. Recent diagnostic innovations have not fully resolved the diagnostic dilemma which separates simple steatosis from advanced NASH. The main treatment approach consists of lifestyle changes yet modern pharmacological treatment options like GLP-1 receptor agonists and FXR agonists present novel prospects for managing NAFLD. Early risk identification together with multidisciplinary strategies along with novel targeted interventions must be developed due to the growing prevalence of NAFLD and its widespread consequences. Researchers need to invest in two main areas: improving FDA-sanctioned pharmacological treatments together with enhancing non-invasive diagnostic methods to achieve better patient results while reducing the long-term effects of NAFLD.

REFERENCES

1. Wong, V. W., Ekstedt, M., Wong, G. L., & Hagström, H. (2023). Changing epidemiology, global trends and implications for outcomes of NAFLD. *Journal of Hepatology*, *79*(3), 842-852. https://doi.org/10.1016/j.jhep.2023.04.036
2. Schwenger, K. J. (2014). Clinical approaches to non-alcoholic fatty liver disease. *World Journal of Gastroenterology*, *20*(7), 1712. https://doi.org/10.3748/wjg.v20.i7.1712
3. El-Kader, S. M. (2015). Non-alcoholic fatty liver disease: The diagnosis and management. *World Journal of Hepatology*, *7*(6), 846. https://doi.org/10.4254/wjh.v7.i6.846
4. Bertot, L. C., & Adams, L. (2016). The natural course of non-alcoholic fatty liver disease. *International Journal of Molecular Sciences*, *17*(5), 774. https://doi.org/10.3390/ijms17050774
5. Neuschwander-Tetri, B. A. (2017). Non-alcoholic fatty liver disease. *BMC Medicine*, *15*(1). https://doi.org/10.1186/s12916-017-0806-8
6. Ruze, R., Liu, T., Zou, X., Song, J., Chen, Y., Xu, R., Yin, X., & Xu, Q. (2023). Obesity and type 2 diabetes mellitus: Connections in epidemiology, pathogenesis, and treatments. *Frontiers in Endocrinology*, *14*. https://doi.org/10.3389/fendo.2023.1161521
7. El Hadi, H., Di Vincenzo, A., Vettor, R., & Rossato, M. (2019). Cardio-metabolic disorders in non-alcoholic fatty liver disease. *International Journal of Molecular Sciences*, *20*(9), 2215. https://doi.org/10.3390/ijms20092215
8. Jarvis, H., Craig, D., Barker, R., Spiers, G., Stow, D., Anstee, Q. M., & Hanratty, B. (2020). Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies. *PLOS Medicine*, *17*(4), e1003100. https://doi.org/10.1371/journal.pmed.1003100
9. Hassen, G., Singh, A., Belete, G., Jain, N., De la Hoz, I., Camacho-Leon, G. P., Dargie, N. K., Carrera, K. G., Alemu, T., Jhaveri, S., & Solomon, N. (2022). Nonalcoholic fatty liver disease: An emerging modern-day risk factor for cardiovascular disease. *Cureus*. https://doi.org/10.7759/cureus.25495
10. Bali, A. D., Rosenzveig, A., Frishman, W. H., & Aronow, W. S. (2023). Nonalcoholic fatty liver disease and cardiovascular disease: Causation or association. *Cardiology in Review*, *32*(5), 453-462. https://doi.org/10.1097/crd.0000000000000537
11. Huang, D. Q., El-Serag, H. B., & Loomba, R. (2020). Global epidemiology of NAFLD-related HCC: Trends, predictions, risk factors and prevention. *Nature Reviews Gastroenterology & Hepatology*, *18*(4), 223-238. https://doi.org/10.1038/s41575-020-00381-6
12. Moszak, M., Szulińska, M., Walczak-Gałęzewska, M., & Bogdański, P. (2021).

Nutritional approach targeting gut microbiota in NAFLD—To date. *International Journal of Environmental Research and Public Health*, *18*(4), 1616. https://doi.org/10.3390/ijerph18041616

13. Mantovani, A., & Dalbeni, A. (2021). Treatments for NAFLD: State of art. *International Journal of Molecular Sciences*, *22*(5), 2350. https://doi.org/10.3390/ijms22052350
14. Abdelhameed, F., Kite, C., Lagojda, L., Dallaway, A., Chatha, K. K., Chaggar, S. S., Dalamaga, M., Kassi, E., Kyrou, I., & Randeva, H. S. (2024). Non-invasive scores and serum biomarkers for fatty liver in the era of metabolic dysfunction-associated Steatotic liver disease (MASLD): A comprehensive review from NAFLD to MAFLD and MASLD. *Current Obesity Reports*, *13*(3), 510-531. https://doi.org/10.1007/s13679-024-00574-z
15. Clayton-Chubb, D., Kemp, W., Majeed, A., Lubel, J. S., Hodge, A., & Roberts, S. K. (2023). Understanding NAFLD: From case identification to interventions, outcomes, and future perspectives. *Nutrients*, *15*(3), 687. https://doi.org/10.3390/nu15030687
16. Figueiredo, P. S., Inada, A., Fernandes, M. R., Arakaki, D. G., Freitas, K., Guimarães, R. A., Do Nascimento, V. A., & Hiane, P. A. (2018). An overview of novel dietary supplements and food ingredients in patients with metabolic syndrome and non-alcoholic fatty liver disease. *Molecules*, *23*(4), 877. https://doi.org/10.3390/molecules23040877
17. Sabir, U., Irfan, H. M., Alamgeer, Ullah, A., Althobaiti, Y. S., & Asim, M. H. (2022). Reduction of hepatic steatosis, oxidative stress, inflammation, ballooning and insulin resistance after therapy with Safranal in NAFLD animal model: A new approach. *Journal of Inflammation Research*, *15*, 1293-1316. https://doi.org/10.2147/jir.s354878
18. Paternostro, R., & Trauner, M. (2022). Current treatment of non-alcoholic fatty liver disease. *Journal of Internal Medicine*, *292*(2), 190-204. https://doi.org/10.1111/joim.13531
19. Ho, A., Kiener, T., Nguyen, Q., & Le, Q. A. (2024). Effect of statin use on liver enzymes and lipid profile in patients with non-alcoholic fatty liver disease (NAFLD). *Journal of Clinical Lipidology*, *18*(4), e501-e508. https://doi.org/10.1016/j.jacl.2024.03.003
20. Dama, A., Shpati, K., Daliu, P., Dumur, S., Gorica, E., & Santini, A. (2024). Targeting metabolic diseases: The role of nutraceuticals in modulating oxidative stress and inflammation. *Nutrients*, *16*(4), 507. https://doi.org/10.3390/nu16040507